Notizie AIOM – anno XV – Pagina 96

23 Gennaio 2017

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics

It is not understood why healthy tissues can exhibit varying levels of sensitivity to the same toxic stimuli. Using BH3 profiling, we find that mitochondria of many adult somatic tissues, including brain, heart, and kidneys, are profoundly refractory to pro-apoptotic signaling, ...
Leggi tutto

20 Gennaio 2017

Statement from FDA Commissioner Robert Califf, M.D. announcing new draft guidances on medical product communications

18 gennaio 2017 - We recognize that there is a high level of interest regarding FDA’s views on communications about medical products. We are committed to an ongoing dialogue with industry and other stakeholders, and, when needed, providing guidance to clarify the agency’s ...
Leggi tutto

20 Gennaio 2017

Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review

Both stereotactic radiotherapy (SRT) and immune- or targeted therapy play an increasingly important role in personalized treatment of metastatic disease. Concurrent application of both therapies is rapidly expanding in daily clinical practice. In this systematic review we ...
Leggi tutto

20 Gennaio 2017

Statement from FDA Commissioner Robert Califf, M.D. announcing FDA Oncology Center of Excellence launch

19 gennaio 2017 - Today the U.S. Food and Drug Administration is establishing the Oncology Center of Excellence (OCE) and appointing Dr. Richard Pazdur as its director. This will make oncology the first disease area to have a coordinated clinical review of drugs, biologics ...
Leggi tutto

20 Gennaio 2017

Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma

Significant controversy exists as to which treatment modality is most effective for small, solitary hepatocellular carcinomas (HCCs): radiofrequency ablation (RFA), surgical resection (RXN), or transplantation (TXP). Size cutoff values ranging from 20 to 50 mm have been ...
Leggi tutto

20 Gennaio 2017

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. A Randomized Clinical Trial

Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. To determine whether zoledronic acid administered every 12 weeks ...
Leggi tutto

20 Gennaio 2017

19 gennaio 2017 – AIFA e AGCM firmano Protocollo d’intesa a tutela della salute pubblica

20 Gennaio 2017

19 gennaio 2017 – Master di I livello in “Comunicazione al pubblico del beneficio/rischio in medicina: diritti, doveri e responsabilità”

20 Gennaio 2017

FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma

The U.S. Food and Drug Administration (FDA) today approved ibrutinib for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication ...
Leggi tutto

19 Gennaio 2017

16 gennaio 2017 – Report ECDC sull’influenza stagionale: categorie a rischio ancora in tempo per la vaccinazione

LAVORIAMO CON

News

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

MIASTENIA GRAVIS, 15MILA PERSONE COLPITE IN ITALIA. “UN’INSTALLAZIONE IMMERSIVA PER COMPRENDERE LA VITA DEI PAZIENTI E AUMENTARE LA CONSAPEVOLEZZA”

MELANOMA, IN ITALIA POSSONO ESSERE “EREDITARI” 2.600 CASI L’ANNO. IMI: “LA PREVENZIONE SIA ANCHE ESAMI GENETICI E SORVEGLIANZA CUTANEA”

Notizie AIOM – anno XV

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics

Statement from FDA Commissioner Robert Califf, M.D. announcing new draft guidances on medical product communications

Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review

Statement from FDA Commissioner Robert Califf, M.D. announcing FDA Oncology Center of Excellence launch

Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. A Randomized Clinical Trial

19 gennaio 2017 – AIFA e AGCM firmano Protocollo d’intesa a tutela della salute pubblica

19 gennaio 2017 – Master di I livello in “Comunicazione al pubblico del beneficio/rischio in medicina: diritti, doveri e responsabilità”

FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma

16 gennaio 2017 – Report ECDC sull’influenza stagionale: categorie a rischio ancora in tempo per la vaccinazione